A number of other brokerages also recently commented on AZN. JPMorgan Chase & Co. reissued a neutral rating and issued a GBX 4,800 ($59.41) price target on shares of AstraZeneca plc in a report on Thursday, July 21st. Jefferies Group increased their price target on AstraZeneca plc from GBX 4,600 ($56.93) to GBX 4,800 ($59.41) and gave the company a hold rating in a report on Thursday, July 14th. BNP Paribas reissued an outperform rating and issued a GBX 5,000 ($61.88) price target on shares of AstraZeneca plc in a report on Wednesday, June 15th. HSBC set a GBX 4,815 ($59.59) price target on AstraZeneca plc and gave the company a neutral rating in a report on Tuesday, August 2nd. Finally, Beaufort Securities reissued a hold rating on shares of AstraZeneca plc in a report on Wednesday, August 10th. Five analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. AstraZeneca plc presently has a consensus rating of Hold and a consensus target price of GBX 4,937.91 ($61.11).
AstraZeneca plc (LON:AZN) opened at 5051.00 on Friday. The stock has a 50 day moving average price of GBX 5,004.92 and a 200-day moving average price of GBX 4,463.08. The firm’s market cap is GBX 63.90 billion. AstraZeneca plc has a 12-month low of GBX 3,680.00 and a 12-month high of GBX 5,505.00.
The firm also recently announced a dividend, which was paid on Monday, September 12th. Investors of record on Thursday, August 11th were given a GBX 68.70 ($0.85) dividend. This represents a yield of 1.37%. The ex-dividend date was Thursday, August 11th.
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.